Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Sep 06, 2022

BUY
$27.52 - $37.99 $2,256 - $3,115
82 New
82 $13,000
Q2 2022

Aug 12, 2022

SELL
$27.52 - $37.99 $2,256 - $3,115
-82 Closed
0 $0
Q1 2022

Sep 06, 2022

BUY
$30.71 - $45.71 $2,518 - $3,748
82 New
82 $2,000
Q3 2021

Oct 06, 2021

SELL
$40.26 - $57.37 $7,327 - $10,441
-182 Closed
0 $0
Q2 2021

Jul 13, 2021

BUY
$54.88 - $79.29 $603 - $872
11 Added 6.43%
182 $10,000
Q1 2021

Apr 30, 2021

SELL
$70.65 - $96.76 $353 - $483
-5 Reduced 2.84%
171 $12,000
Q4 2020

Jan 25, 2021

BUY
$58.41 - $89.06 $10,104 - $15,407
173 Added 5766.67%
176 $16,000
Q3 2020

Oct 29, 2020

BUY
$41.13 - $62.45 $123 - $187
3 New
3 $0
Q2 2020

Aug 05, 2020

SELL
$25.95 - $43.15 $596 - $992
-23 Closed
0 $0
Q1 2020

May 12, 2020

SELL
$26.15 - $77.24 $16,657 - $49,201
-637 Reduced 96.52%
23 $1,000
Q4 2019

Jan 17, 2020

SELL
$60.18 - $154.77 $481 - $1,238
-8 Reduced 1.2%
660 $48,000
Q3 2019

Nov 07, 2019

BUY
$140.29 - $189.96 $92,170 - $124,803
657 Added 5972.73%
668 $97,000
Q1 2019

May 15, 2019

SELL
$89.33 - $163.65 $46,719 - $85,588
-523 Reduced 97.94%
11 $2,000
Q4 2018

Jan 23, 2019

SELL
$81.94 - $139.71 $163 - $279
-2 Reduced 0.37%
534 $51,000
Q3 2018

Oct 25, 2018

SELL
$138.11 - $169.04 $966 - $1,183
-7 Reduced 1.29%
536 $0
Q2 2018

Aug 07, 2018

BUY
$140.36 - $175.76 $75,513 - $94,558
538 Added 10760.0%
543 $0
Q4 2016

Jun 03, 2019

SELL
N/A
-6 Reduced 54.55%
5 $0
Q1 2016

Jun 03, 2019

BUY
N/A
11
11 $2,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Ifp Advisors, Inc Portfolio

Follow Ifp Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.